Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY 11-7082 |
Synonyms | |
Therapy Description |
BAY 11-7082 is an inhibitor of kB kinase (IKK) 1 and 2, which may result in inhibition of NFkappaB pathway signaling leading to cell death (PMID: 23527154, PMID: 32770097). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY 11-7082 | BAY117082|BAY11 7082|BAY 117082|BAY11-7821|BAY11 7082|BAY11-7082 | BAY 11-7082 is an inhibitor of kB kinase (IKK) 1 and 2, which may result in inhibition of NFkappaB pathway signaling leading to cell death (PMID: 23527154, PMID: 32770097). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS act mut | Advanced Solid Tumor | predicted - sensitive | BAY 11-7082 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BAY 11-7082 induced apoptosis and decreased Akt signaling, viability, and colony formation in cancer cells harboring activating HRAS mutations in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38982514). | 38982514 |
NRAS act mut | melanoma | sensitive | BAY 11-7082 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BAY 11-7082 induced apoptosis and decreased Akt signaling, viability, and colony formation in melanoma cell lines harboring activating NRAS mutations in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38982514). | 38982514 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|